Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.97M rose 123.4% year over year, ahead of the +76.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 9.0% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.
Context
- Stock-based compensation amounted to 45.9% of revenue in FY2025, down 1.4 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +123.4% holds above the trailing-twelve-month pace of +76.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.02M USD
- Year-over-year change
- +25.9%
- 4-year CAGR
- -6.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.02M | +25.9% |
| FY2024 | 2024-12-31 | 4.78M | -48.5% |
| FY2023 | 2023-12-31 | 9.28M | -15.0% |
| FY2022 | 2022-12-31 | 10.91M | +38.2% |
| FY2021 | 2021-12-31 | 7.9M | — |
Stock-Based Compensation vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +76.4% is the 3rd highest of 10, against a peer median of +7.9%.
- Stock-based compensation amounts to 39.9% of revenue for TNXP, versus a peer median of 344.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.47M USD | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $13.96M USD | +64.9% | +21.7% | 23652.5% | |
| LTM Mar 2026 | $9.79M USD | -31.5% | +8.6% | — | |
| LTM Mar 2026 | $9.79M USD | -43.4% | -24.8% | 853.3% | |
| LTM Mar 2026 | $7.82M USD | +99.9% | +15.9% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | $7M USD | +76.4% | -18.0% | 39.9% | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding TNXP) | — | +7.9% | +0.1% | 344.3% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.9M | 10.91M | 9.28M | 4.78M | 6.02M |
| Change in Working Capital | 5.78M | (2K) | (35K) | 5.78M | 8.55M |
| Accounts Receivables | 0 | 0 | 0 | (3.68M) | (2.62M) |
| Inventory | 0 | 0 | 61K | 3.74M | 1.73M |
| Accounts Payables | 3.53M | (1.05M) | (3.49M) | 927K | 2.99M |
| Other Working Capital | 2.26M | 1.04M | 3.39M | 4.79M | 6.44M |
| Other Non-Cash Items | 3M | 10.91M | 1.12M | 55.14M | 7.69M |
| Operating Cash Flow | (75.56M) | (98.05M) | (102M) | (60.93M) | (99.84M) |
| Capital Expenditures | (35.31M) | (48.15M) | (7.9M) | (120K) | (3.37M) |
| Acquisitions (Net) | 0 | 0 | (22.17M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 999K | 0 | (1.16M) |
| Investing Cash Flow | (35.31M) | (48.15M) | (29.07M) | (120K) | (4.53M) |
| Debt Repayment | 0 | 0 | 8.94M | (2.35M) | (9.65M) |
| Common Stock Issued | 212.39M | 94.46M | 18.94M | 140.2M | 237.94M |
| Common Stock Repurchased | 0 | 0 | (13.97M) | 0 | (13.76M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 98K | 40K | 22.6M | (2.97M) | 0 |
| Financing Cash Flow | 212.49M | 87.84M | 36.52M | 134.87M | 214.53M |
| Effect of Forex Changes | (31K) | (74K) | (65K) | 4K | (31K) |
| Net Change in Cash | 101.59M | (58.43M) | (94.62M) | 73.83M | 110.13M |
| Free Cash Flow | (110.86M) | (146.2M) | (109.9M) | (61.05M) | (103.21M) |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.